Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing–remitting multiple sclerosis in a real-world clinical setting: PROTEC

BACKGROUND: Patient-reported outcomes (PRO) and clinical outcomes give a broad assessment of relapsing–remitting multiple sclerosis (RRMS) disease. OBJECTIVE: The aim is to evaluate the effectiveness of delayed-release dimethyl fumarate (DMF) on disease activity and PROs in patients with RRMS in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, T, Brochet, B, Brambilla, L, Giacomini, PS, Montalbán, X, Vasco Salgado, A, Su, R, Bretagne, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891011/
https://www.ncbi.nlm.nih.gov/pubmed/31832225
http://dx.doi.org/10.1177/2055217319887191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891011/
https://www.ncbi.nlm.nih.gov/pubmed/31832225
http://dx.doi.org/10.1177/2055217319887191

Ejemplares similares